Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

This study is currently recruiting participants.

Verified February 2013 by H. Lee Moffitt Cancer Center and Research Institute

Study NCT00840931 Information provided by H. Lee Moffitt Cancer Center and Research Institute

First Received on February 4, 2009. Last Updated on February 13, 2013 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Leukemia

Additional conditions recognized in this trial

More general conditions related to this trial

Interventions listed in this trial

lenalidomide
bystander vaccine

Additional drug interventions recognized in this trial

Thalidomide

More general drug interventions related to this trial

Sponsors listed in this trial